Tuberculosis

DNA Therapeutic Vaccine Tested in Cornell Mouse Model

Published in Gene Therapy Weekly, September 21st, 2000

A therapeutic DNA vaccine against Mycobacterium tuberculosis was effective in reducing reactivation of tuberculosis in the Cornell mouse model, researchers in the United Kingdom reported.

"The standard model for persistence and reactivation of M. tuberculosis is the 'Cornell model,'" stated M. Pudney and colleagues from GlaxoWellcome, England, at the American Society for Microbiology Conference on Tuberculosis, Past, Present, and Future, held in New York, New York. "TB-infected mice are treated until mycobacteria can no longer be cultured from lung or spleen. The treatment is withdrawn and animals are rested before being immunosuppressed to reactivate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry